Opioids - As enacted, clarifies that a physician licensed in this state is the only healthcare provider authorized to prescribe a buprenorphine product for a FDA-approved use in recovery or medication-assisted treatment; revises criteria for providers not licensed in this state to prescribe a buprenorphine product for the treatment of opioid use disorder. - Amends TCA Title 33; Title 41; Title 53 and Title 63.

HB 1239 clarifies that only physicians licensed in Tennessee may prescribe buprenorphine for FDA-approved uses in opioid recovery or medication-assisted treatment. It also establishes new requirements for non-Tennessee-licensed healthcare providers (such as those working in correctional facilities) to prescribe buprenorphine for opioid use disorder: they must hold a federal DEA registration, be employed by or contract with a correctional facility or jail, and have clinical protocols for medication-assisted treatment. The bill revises existing law to limit prescribing authority while creating specific pathways for correctional healthcare providers. It takes effect on July 1, 2025.